Resumo

Human T-lymphotropic virus 1 (HTLV-1), a human retrovirus, is the causative agent of an aggressive T-cell leukemia known as adult T-cell leukemia (ATL) and a neurodegenerative disease called HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP), besides other inflammatory diseases. Nevertheless, therapeutic approaches to HTLV-1-related pathologies are still limited. The aim of this study is the evaluation of two new adamantane derivatives, ADA1 and ADA2 having in common the moiety (C10H15), for which antiviral properties had already been described to Influenza, Rubella virus and HIV. Preliminary data are being evaluated in MT2 cells, a human cell lineage permanently infected with HTLV-1. The citotoxicity of the derivatives was evaluated in the concentrations of 1µM, 0.01µM and 0.0001µM for 72h (MTT assay), and, concomitantly a Western Blot (WB) assay was performed in the same conditions by using the total proteins extracted from the cells, after centrifugation. The supernatant of these cells was used to detect cytokines in a flow citometry assay (CBA Th1/Th2/Th17 - BD). Both derivatives did not present toxicity to MT2 cells in any of the dilutions tested. In the WB assay, a pool of HTLV-1 serum from positive HAM/TSP patients indicated variation in the protein profile of MT2 treated cells that were drug and concentration dependent, highlighting the protein modulation by ADA1 in the 0.0001µM concentration. The cytokines profile analyzed did not demonstrate significant variation, however, the supernatant of MT2 treated cells with ADA1 in the 0.01µM concentration showed an expression a little higher of IL-6, IL-10 and IFN-γ than the other drug and concentrations. These preliminary data demonstrate that ADA1 can be a possible antiviral candidate for HTLV-1 infection.